{"filing":{"accession_number":"0001193125-26-342378","cik":"0002104204","ticker":"ALMR","company_name":"Alamar Biosciences, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"ck0002104204-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2104204/000119312526342378/ck0002104204-20260810.htm"},"events":[{"id":26567,"run_id":24149,"accession_number":"0001193125-26-342378","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a straightforward earnings release for Q2 2026 financial results. The 8-K Item 2.02 discloses quarterly revenue of $29.4 million (82% YoY growth), gross margin of 60%, operating loss of $13.5 million, and net loss of $13.2 million, along with full-year 2026 revenue guidance of $116–$120 million. The press release is attached as Exhibit 99.1 and includes detailed financial statements and operational highlights. This is material to investors assessing the registrant's financial performance and trajectory.","company_name":"Alamar Biosciences, Inc.","ticker":"ALMR","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27734,"accession_number":"0001193125-26-342378","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release for Q2 2026 financial results. The 8-K Item 2.02 discloses quarterly revenue of $29.4 million (82% YoY growth), gross margin of 60%, operating loss of $13.5 million, and net loss of $13.2 million, along with full-year 2026 revenue guidance of $116–$120 million. The press release is attached as Exhibit 99.1 and includes detailed financial statements and operational highlights. This is material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:17:37.986098+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27734,"accession_number":"0001193125-26-342378","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a straightforward earnings release for Q2 2026 financial results. The 8-K Item 2.02 discloses quarterly revenue of $29.4 million (82% YoY growth), gross margin of 60%, operating loss of $13.5 million, and net loss of $13.2 million, along with full-year 2026 revenue guidance of $116–$120 million. The press release is attached as Exhibit 99.1 and includes detailed financial statements and operational highlights. This is material to investors assessing the registrant's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:17:37.986098+00:00","company_name":"Alamar Biosciences, Inc.","ticker":"ALMR","filing_date":"2026-08-10"}]}